Patent ID: 8008275

Claim:
A method for treating a human afflicted with Acquired immunodeficiency Syndrome, comprising the step of administering to said human an active ingredient which is at least one oligosaccharide having a structure selected from the group of the following 33 oligosaccharide structures: Structure 1 6 Pyr< >Galβ1-4GlcNAcβ1-3Fuc 4 Structure 2 structure 3 structure 4 (SO 3 )GlcNAc-Fuc-Fuc structure 5 Fuc-(SO 3 )GlcNAc-Fuc structure 6 GlcNAc-(SO 3 )Gal-Fuc structure 7 Gal-(SO 3 )Gal-GlcNAc-Fuc-Fuc structure 8 Gal-(SO 3 )Gal-GlcNAc-Fuc-Fuc structure 9 GlcNAc-Fuc-(SO 3 )Gal-Fuc structure 10 Pyr(4,6)Gal-Gal-Fuc structure 11 Pyr(4,6)Gal-Gal-Fuc-GlcNAc structure 12 structure 13 structure 14 structure 15 structure 16 structure 17 structure 18 Gal-GlcNAc-Fuc(SO 3 )-GlcNAc-Fuc structure 19 Gal-GlcNAc-Ara(SO 3 )-GlcNAc-Fuc structure 20 Gal-GalNAc-Fuc(SO 3 )-GlcNAc-Fuc structure 21 Gal-GalNAc-Fuc(SO 3 )-GalNAc-Fuc structure 22 Gal-GlcNAc-Fuc(SO 3 )-GalNAc-Fuc structure 23 Gal-GalNAc-Ara(SO 3 )-GlcNAc-Fuc structure 24 Gal-GalNAc-Ara(SO 3 )-GalNAc-Fuc structure 25 Gal-GlcNAc-Ara(SO 3 )-GalNAc-Fuc structure 26 GlcNAc-Fuc(SO 3 )-GlcNAc-Fuc-Fuc structure 27 GlcNAc-Ara(SO 3 )-GlcNAc-Fuc-Fuc structure 28 GalNAc-Fuc(SO 3 )-GlcNAc-Fuc-Fuc structure 29 GalNAc-Fuc(SO 3 )-GalNAc-Fuc-Fuc structure 30 GlcNAc-Fuc(SO 3 )-GalNAc-Fuc-Fuc structure 31 GalNAc-Ara(SO 3 )-GlcNAc-Fuc-Fuc structure 32 GalNAc-Ara(SO 3 )-GalNAc-Fuc-Fuc structure 33 GlcNAc-Ara(SO 3 )-GalNAc-Fuc-Fuc.